



## Clinical trial results:

### An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment

#### Summary

EudraCT number	2015-003536-12
Trial protocol	Outside EU/EEA
Global end of trial date	26 December 2013

#### Results information

Result version number	v1 (current)
This version publication date	04 January 2017
First version publication date	04 January 2017

#### Trial information

##### Trial identification

Sponsor protocol code	CIGE025B1301E1
-----------------------	----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01328886
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH 4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	26 December 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 December 2013
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The main objective of the trial was to assess the long-term safety and tolerability of omalizumab as add-on therapy in Japanese pediatric subjects with inadequately controlled allergic asthma despite current recommended treatment.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 March 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Japan: 38
Worldwide total number of subjects	38
EEA total number of subjects	0

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	21
Adolescents (12-17 years)	17
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 15 centers in Japan.

### Pre-assignment

Screening details:

This study was the extension study of the core study CIGE025B1301 (EudraCT Number: 2015-003534-27).

### Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

The study was open label study, hence no blinding was performed.

### Arms

Arm title	Omalizumab
-----------	------------

Arm description:

Omalizumab 75 to 375 mg was administered subcutaneously (sc) every 2 or 4 weeks depending on the dose. Omalizumab dose was individualized for each subject, based on their body weight and total serum immunoglobulin E (IgE) level at screening visit.

Arm type	Experimental
Investigational medicinal product name	Omalizumab
Investigational medicinal product code	IGE025B
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were administered with Omalizumab 75 to 375 mg subcutaneously every 2 or 4 weeks.

Number of subjects in period 1	Omalizumab
Started	38
Completed	35
Not completed	3
Consent withdrawn by subject	2
Lack of efficacy	1

## Baseline characteristics

### Reporting groups

Reporting group title	Overall period
-----------------------	----------------

Reporting group description: -

Reporting group values	Overall period	Total	
Number of subjects	38	38	
Age categorical			
Units: Subjects			
Children (2-11 years)	21	21	
Adolescents (12-17 years)	17	17	
Age continuous			
Units: years			
arithmetic mean	11.5		
standard deviation	± 2.52	-	
Gender categorical			
Units: Subjects			
Female	15	15	
Male	23	23	

## End points

### End points reporting groups

Reporting group title	Omalizumab
Reporting group description: Omalizumab 75 to 375 mg was administered subcutaneously (sc) every 2 or 4 weeks depending on the dose. Omalizumab dose was individualized for each subject, based on their body weight and total serum immunoglobulin E (IgE) level at screening visit.	

### Primary: Number of subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), AE leading to discontinuation and who died

End point title	Number of subjects with Adverse Events (AEs), Serious Adverse Events (SAEs), AE leading to discontinuation and who died <sup>[1]</sup>
End point description: AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. The analysis was performed on safety set population, defined subjects with at least one dose of study medication during the study..	
End point type	Primary
End point timeframe: From day 1 to 30 days post last study treatment	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Only descriptive summary statistics was planned for this outcome measure.	

End point values	Omalizumab			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Subjects				
AEs	38			
SAEs	10			
SAEs other than asthma exacerbation	4			
Asthma exacerbation	7			
Death	0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events are monitored from date of First Subject First Visit (FSFV) until Last Subject Last Visit (LSLV). All other adverse events are monitored from First Subject First Treatment until LSLV

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Omalizumab
-----------------------	------------

Reporting group description:

Omalizumab 75 to 375 mg was administered sc every 2 or 4 weeks depending on the dose. Omalizumab dose was individualized for each subject, based on their body weight and total serum IgE level at screening visit.

Serious adverse events	Omalizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 38 (26.32%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Foot fracture			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	7 / 38 (18.42%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			

Appendicitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonsillar abscess			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tonsillitis bacterial			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Viral pharyngitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	Omalizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	38 / 38 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
General disorders and administration			

site conditions			
Administration site pain			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Application site erythema			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Application site swelling			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Discomfort			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Injection site eczema			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Injection site erythema			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Injection site swelling			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	4		
Malaise			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	9 / 38 (23.68%)		
occurrences (all)	14		
Swelling			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Food allergy			



subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1		
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)  Cough subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Nasal congestion subjects affected / exposed occurrences (all)  Oropharyngeal discomfort subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)  Rhinitis allergic subjects affected / exposed occurrences (all)  Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	6 / 38 (15.79%) 10  1 / 38 (2.63%) 1  2 / 38 (5.26%) 2  1 / 38 (2.63%) 1  1 / 38 (2.63%) 1  1 / 38 (2.63%) 2  4 / 38 (10.53%) 5  5 / 38 (13.16%) 9		
Psychiatric disorders Conversion disorder subjects affected / exposed occurrences (all)  Dysphoria	1 / 38 (2.63%) 1		

subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Insomnia			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Psychosomatic disease			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Investigations			
Blood pressure diastolic increased			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Urine output decreased			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Arthropod sting			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Contusion			
subjects affected / exposed	8 / 38 (21.05%)		
occurrences (all)	10		
Epicondylitis			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Epiphyseal injury			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Foot fracture			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Hand fracture			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Heat illness			

subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Injury			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Ligament sprain			
subjects affected / exposed	6 / 38 (15.79%)		
occurrences (all)	7		
Scratch			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Wound			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	11 / 38 (28.95%)		
occurrences (all)	16		
Migraine			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Orthostatic intolerance			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Tremor			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Auricular perichondritis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Eye disorders			
Chalazion			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Conjunctivitis allergic			

subjects affected / exposed	5 / 38 (13.16%)		
occurrences (all)	6		
Eczema eyelids			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Eye swelling			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Myopia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Visual acuity reduced			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Abdominal pain			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	6		
Abdominal pain upper			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Cheilitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Constipation			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	4		
Dental caries			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		

Gastritis			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Enterocolitis			
subjects affected / exposed	7 / 38 (18.42%)		
occurrences (all)	9		
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Periodontal disease			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Radicular cyst			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Stomatitis			
subjects affected / exposed	7 / 38 (18.42%)		
occurrences (all)	8		
Toothache			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	6 / 38 (15.79%)		
occurrences (all)	6		
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	4		
Asteatosis			

subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Dermatitis allergic			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Dermatitis atopic			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Dermatitis contact			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Dry skin			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Eczema			
subjects affected / exposed	10 / 38 (26.32%)		
occurrences (all)	11		
Eczema nummular			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Urticaria			
subjects affected / exposed	5 / 38 (13.16%)		
occurrences (all)	6		
Renal and urinary disorders			
Enuresis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Arthropathy			

subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	4		
Growing pains			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Infrapatellar fat pad inflammation			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	3		
Myofascial pain syndrome			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Upper extremity mass			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Infections and infestations			
Body tinea			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Acute tonsillitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Bronchitis			
subjects affected / exposed	3 / 38 (7.89%)		
occurrences (all)	5		
Bronchitis viral			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		

Chronic sinusitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Folliculitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Fungal skin infection			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	6 / 38 (15.79%)		
occurrences (all)	8		
Gingivitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Herpangina			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Hordeolum			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	2		
Impetigo			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Influenza			
subjects affected / exposed	15 / 38 (39.47%)		
occurrences (all)	17		
Injection site infection			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Laryngitis			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Kaposi's varicelliform eruption			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		



Mumps			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	20 / 38 (52.63%)		
occurrences (all)	52		
Oral herpes			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Otitis externa			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	4		
Otitis media			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Otitis media acute			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Parotitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Pharyngitis			
subjects affected / exposed	7 / 38 (18.42%)		
occurrences (all)	10		
Pneumonia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Respiratory tract infection viral			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Sinobronchitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	3		

Streptococcal infection			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences (all)	3		
Upper respiratory tract infection			
subjects affected / exposed	14 / 38 (36.84%)		
occurrences (all)	34		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported